Author:
Despiégel Nicolas,Anger Delphine,Martin Monique,Monga Neerav,Cui Qu,Rocchi Angela,Pulgar Sonia,Gilchrist Kim,Refoios Camejo Rodrigo
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical)
Reference51 articles.
1. World Health Organization. Fast facts on HIV. http://www.who.int/hiv/data/fast_facts/en/ . Accessed Nov 10, 2014.
2. Canadian Agency for Drugs and Technologies in Health. https://www.cadth.ca/fr . Accessed May 28, 2015.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60.
4. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results—SINGLE (ING114467). In: Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy: San Francisco; Sept 9–12, 2012.
5. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222–31.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献